Sugemalimab clinical trials
Also written CS1001.
How each study uses sugemalimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the sugemalimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- 24 Jul 2024 · Cejemly · EMEA/H/C/006088 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2018 (5); 1 more planned to start later
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 5 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 5
CStone Pharmaceuticals (11) · Sichuan University (1) · Peking Union Medical College (1) · Shanghai Pulmonary Hospital, Shanghai, China (1) · Sun Yat-sen University (1) · Hunan Cancer Hospital (1) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Sugemalimab is the comparator. A study of two new drugs counts under both.
- 1Cadonilimab · Akeso
Reaching primary completion within a year · 2
Studies that test sugemalimab.
- May 2027Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLCNot applicable · Peking Union Medical College
- Oct 2027Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLCPhase 1/2 · Sichuan University
Studies
Open first, then newest update. How each study uses sugemalimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell LymphomaNot yet recruitingPhase 3CStone PharmaceuticalsNCT05700448Written as SugemalimabHow we know
- Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLCRecruitingPhase 1/2Sichuan UniversityNCT06217757Written as SugemalimabHow we know
- Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLCRecruitingNot applicablePeking Union Medical CollegeNCT07247227Written as Sugemalimab and ChemotherapyHow we know
- Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer PatientsRecruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT06987734Written as Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant SugemalimabHow we know
- Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRTRecruitingPhase 2/3Sun Yat-sen UniversityNCT05623267Written as SugemalimabHow we know
- A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLCRecruitingPhase 2Hunan Cancer HospitalNCT05940532Written as Sugemalimab and ChemotherapyHow we know
- A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung CancerCompletedPhase 3CStone PharmaceuticalsNCT03789604Written as CS1001 monoclonal antibodyHow we know
- A Study of CS1001 in Subjects with Advanced Solid TumorsCompletedPhase 1CStone PharmaceuticalsNCT03744403Written as CS1001How we know
- A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL)CompletedPhase 2CStone PharmaceuticalsNCT03595657Written as CS1001How we know
- Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC PatientsCompletedPhase 1CStone PharmaceuticalsNCT04421352Written as CS1001How we know
- A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction AdenocarcinomaCompletedPhase 3CStone PharmaceuticalsNCT03802591Written as CS1001 monoclonal antibodyHow we know
- A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedPhase 3CStone PharmaceuticalsNCT04187352Written as CS1001+ Fluorouracil+CisplatinHow we know
- A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung CancerCompletedPhase 3CStone PharmaceuticalsNCT03728556Written as CS1001 monoclonal antibodyHow we know
- A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid TumorsStatus unknownPhase 1Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT04472858Written as CS1001How we know
- A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin LymphomaCompletedPhase 2CStone PharmaceuticalsNCT03505996Written as CS1001How we know
- A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid TumorsCompletedPhase 1CStone PharmaceuticalsNCT03312842Written as CS1001How we know
- A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid TumorsCompletedPhase 1/2CStone PharmaceuticalsNCT04200404Written as CS1001How we know
Given beside what is tested · 1 — sugemalimab is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with sugemalimab
Codes
What other systems call sugemalimab · ClinicalTrials.gg INT001923
- MeSH (NLM) C000723018sugemalimabOne source ClinicalTrials.gov
- UNII (FDA) 90IQR2I6TRSUGEMALIMABOne source FDA
- NCI Thesaurus C154550SugemalimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000723018 | sugemalimab | One source ClinicalTrials.gov |
| UNII (FDA) | 90IQR2I6TR | SUGEMALIMAB | One source FDA |
| NCI Thesaurus | C154550 | Sugemalimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.